Stock listing
HKEX:2181 Mabpharm Limited (邁博藥業) 股價
Follow Mabpharm Limited into a list and get an email when it puts out news.
Share price · HKEX:2181
$0.47 HKD 0.00 (0.0%)
Close on Nov 20, 2026
- Day range
- $0.47 – $0.47 HKDNov 20, 2026
- Market cap
- $1.94B HKDAt the close on Nov 20, 2026 · price × 4.12B shares outstanding
- 52-week range
- $0.31 – $0.81 HKDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $20,035 HKDMedian day 20,000 shares · 17 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · HKEX:2181 · HKD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.47 | 0.00 | 0.0% | $0.47 | $0.47 | $0.47 | 0 | |
| $0.47 | -0.025 | -5.1% | $0.47 | $0.47 | $0.47 | 0 | |
| $0.495 | +0.005 | +1.0% | $0.435 | $0.495 | $0.435 | 34,000 | |
| $0.49 | 0.00 | 0.0% | $0.425 | $0.51 | $0.425 | 22,000 | |
| $0.49 | 0.00 | 0.0% | $0.49 | $0.49 | $0.49 | 0 | |
| $0.49 | +0.05 | +11.4% | $0.425 | $0.51 | $0.425 | 22,000 | |
| $0.44 | 0.00 | 0.0% | $0.44 | $0.44 | $0.44 | 2,000 | |
| $0.44 | -0.04 | -8.3% | $0.43 | $0.44 | $0.43 | 26,000 | |
| $0.48 | 0.00 | 0.0% | $0.48 | $0.48 | $0.48 | 0 | |
| $0.48 | 0.00 | 0.0% | $0.48 | $0.48 | $0.48 | 0 | |
| $0.48 | +0.015 | +3.2% | $0.425 | $0.485 | $0.42 | 202,000 | |
| $0.465 | +0.04 | +9.4% | $0.495 | $0.52 | $0.465 | 260,000 | |
| $0.425 | -0.005 | -1.2% | $0.435 | $0.435 | $0.425 | 240,000 | |
| $0.43 | -0.005 | -1.1% | $0.425 | $0.435 | $0.425 | 22,000 | |
| $0.435 | 0.00 | 0.0% | $0.435 | $0.435 | $0.435 | 0 | |
| $0.435 | 0.00 | 0.0% | $0.43 | $0.435 | $0.425 | 72,000 | |
| $0.435 | 0.00 | 0.0% | $0.435 | $0.435 | $0.435 | 0 | |
| $0.435 | -0.005 | -1.1% | $0.425 | $0.435 | $0.425 | 102,000 | |
| $0.44 | -0.02 | -4.3% | $0.43 | $0.44 | $0.43 | 42,000 | |
| $0.46 | +0.02 | +4.5% | $0.495 | $0.50 | $0.46 | 52,000 | |
| $0.44 | -0.06 | -12.0% | $0.55 | $0.55 | $0.44 | 36,000 | |
| $0.50 | 0.00 | 0.0% | $0.50 | $0.50 | $0.50 | 20,000 | |
| $0.50 | 0.00 | 0.0% | $0.50 | $0.515 | $0.50 | 0 | |
| $0.50 | 0.00 | 0.0% | $0.50 | $0.50 | $0.50 | 0 | |
| $0.50 | 0.00 | 0.0% | $0.50 | $0.515 | $0.50 | 80,000 | |
| $0.50 | 0.00 | 0.0% | $0.50 | $0.515 | $0.50 | 80,000 | |
| $0.50 | -0.005 | -1.0% | $0.50 | $0.515 | $0.50 | 80,000 | |
| $0.505 | 0.00 | 0.0% | $0.505 | $0.505 | $0.505 | 0 | |
| $0.505 | +0.005 | +1.0% | $0.50 | $0.515 | $0.50 | 80,000 | |
| $0.50 | 0.00 | 0.0% | $0.50 | $0.50 | $0.50 | 0 | |
| $0.50 | 0.00 | 0.0% | $0.50 | $0.50 | $0.50 | 0 | |
| $0.50 | -0.005 | -1.0% | $0.43 | $0.50 | $0.43 | 6,000 | |
| $0.505 | +0.015 | +3.1% | $0.485 | $0.52 | $0.485 | 20,000 | |
| $0.49 | +0.04 | +8.9% | $0.495 | $0.495 | $0.49 | 2,000 | |
| $0.45 | -0.025 | -5.3% | $0.535 | $0.535 | $0.45 | 56,000 | |
| $0.475 | -0.02 | -4.0% | $0.475 | $0.475 | $0.475 | 0 | |
| $0.495 | -0.015 | -2.9% | $0.495 | $0.495 | $0.495 | 0 | |
| $0.51 | +0.115 | +29.1% | $0.405 | $0.51 | $0.405 | 16,000 | |
| $0.395 | +0.02 | +5.3% | $0.35 | $0.40 | $0.35 | 46,000 | |
| $0.375 | -0.045 | -10.7% | $0.375 | $0.375 | $0.375 | 2,000 | |
| $0.42 | +0.02 | +5.0% | $0.42 | $0.50 | $0.415 | 4,000 | |
| $0.40 | +0.01 | +2.6% | $0.385 | $0.40 | $0.385 | 210,000 | |
| $0.39 | -0.03 | -7.1% | $0.41 | $0.41 | $0.39 | 112,000 | |
| $0.42 | 0.00 | 0.0% | $0.42 | $0.42 | $0.42 | 120,000 | |
| $0.42 | 0.00 | 0.0% | $0.44 | $0.44 | $0.42 | 14,000 | |
| $0.42 | -0.015 | -3.4% | $0.44 | $0.44 | $0.42 | 14,000 | |
| $0.435 | 0.00 | 0.0% | $0.435 | $0.435 | $0.435 | 20,000 | |
| $0.435 | -0.015 | -3.3% | $0.42 | $0.435 | $0.42 | 48,000 | |
| $0.45 | -0.025 | -5.3% | $0.455 | $0.455 | $0.45 | 22,000 | |
| $0.475 | +0.03 | +6.7% | $0.415 | $0.495 | $0.415 | 4,000 | |
| $0.445 | 0.00 | 0.0% | $0.445 | $0.445 | $0.445 | 0 | |
| $0.445 | 0.00 | 0.0% | $0.445 | $0.445 | $0.445 | 10,000 | |
| $0.445 | 0.00 | 0.0% | $0.445 | $0.445 | $0.445 | 30,000 | |
| $0.445 | 0.00 | 0.0% | $0.445 | $0.445 | $0.445 | 0 | |
| $0.445 | 0.00 | 0.0% | $0.445 | $0.445 | $0.445 | 56,000 | |
| $0.445 | 0.00 | 0.0% | $0.445 | $0.445 | $0.445 | 0 | |
| $0.445 | +0.01 | +2.3% | $0.445 | $0.445 | $0.445 | 50,000 | |
| $0.435 | 0.00 | 0.0% | $0.435 | $0.435 | $0.435 | 10,000 | |
| $0.435 | +0.005 | +1.2% | $0.43 | $0.435 | $0.40 | 210,000 | |
| $0.43 | 0.00 | 0.0% | $0.43 | $0.43 | $0.43 | 20,000 | |
| $0.43 | 0.00 | 0.0% | $0.41 | $0.50 | $0.41 | 34,000 | |
| $0.43 | -0.005 | -1.1% | $0.435 | $0.435 | $0.43 | 20,000 | |
| $0.435 | 0.00 | 0.0% | $0.43 | $0.435 | $0.43 | 122,000 | |
| $0.435 | +0.015 | +3.6% | $0.43 | $0.435 | $0.43 | 122,000 |
- Ticker
- HKEX:2181
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- HKEX
- Currency
- HKD
What changed lately
Latest news release · Nov 3, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Latest news
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Nov 3, 2026
Closed $0.465 (+9.4%) on Nov 4, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Oct 6, 2026
Closed $0.50 (0.0%) on Oct 7, 2026
2026 Interim Report
Sep 21, 2026
Closed $0.42 (+5.0%) on Sep 22, 2026
Third Amended and Restated memorandum and articles of association
Jun 26, 2026
Closed $0.42 (0.0%) on Jun 29, 2026
Mabpharm Limited on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 5 in the last 12 months · 5 in all · newest Nov 3, 2026 · oldest 2026
Valuation
P/E 29.6× against a median of 10.3×: 3rd lowest of 4 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $2.19B HKD
- P/E
- 29.6×
- EV/sales
- 3.0×
- EV/EBITDA
- 28.9×
- Price/book
- 8.5×
- Gross margin
- 82.9%
- Operating margin
- 0.7%
- Net margin
- 8.8%
- Debt to equity
- 1.6×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Mabpharm Limited · HKEX:2181 | US$247.3M | US$279.5M | 29.6× | 3.0× | 28.9× | 8.5× | 8.8% | 1.6× | n/a |
| Eikon Therapeutics, Inc. · NASDAQ:EIKN | US$256.8M | US$44.67M | n/a | n/a | n/a | 0.7× | n/a | 0.7× | 1.91 |
| SAB Biotherapeutics, Inc. · NASDAQ:SABS | US$255.7M | US$156.5M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.19 |
| Evommune, Inc. · NYSE:EVMN | US$255.5M | US$86.86M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | 0.96 |
| Editas Medicine, Inc. · NASDAQ:EDIT | US$253.1M | US$119.7M | n/a | 2.4× | n/a | 3.0× | −144.9% | 0.7× | 2.22 |
| Q32 Bio Inc. · NASDAQ:QTTB | US$249.6M | −US$35.66M | 7.7× | −0.7× | −1.9× | 0.9× | 59.8% | 0.0× | 0.59 |
| Turn Therapeutics Inc. · NASDAQ:TTRX | US$247.5M | US$244.2M | n/a | n/a | n/a | 43.5× | n/a | 1.1× | 1.54 |
| Lexeo Therapeutics, Inc. · NASDAQ:LXEO | US$245.1M | US$56.52M | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 1.62 |
| Shandong Boan Biotechnology Company., Limited. Class H · HKEX:6955 | US$242.7M | US$92.94M | 226× | 0.8× | 4.6× | 0.6× | 0.9% | 0.0× | n/a |
| Curocell, Inc. · KRX:372320 | US$239.8M | US$191.4M | n/a | n/a | n/a | 4.5× | n/a | 0.2× | n/a |
| Clinuvel Pharmaceuticals Limited · ASX:CUV | US$238.9M | US$73.38M | 10.3× | 1.1× | 2.6× | 1.3× | 36.0% | 0.0× | n/a |
| Median of the others | US$248.5M | US$89.90M | 10.3× | 1.0× | 2.6× | 1.2× | 18.5% | 0.0× | 1.54 |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Sep 22, 2025 | −5.1% |
| Quarter to Mar 31, 2025 | Apr 22, 2025 | −1.0% |
| Q4 2024 | Mar 26, 2025 | +1.8% |
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 629.4M | 258.2M | 87.2M | 55.9M | 82.9M | 0 | 14.1M | 23.9M | 4.69M |
| Cost of revenue | 107.8M | 38.8M | 11.9M | 15.4M | 16.8M | 0 | |||
| Gross profit | 521.5M | 219.4M | 75.2M | 40.5M | 66.1M | 0 | 14.1M | 23.9M | 4.69M |
| Research and development | 49.3M | 75.2M | 123.2M | 147.9M | 263.6M | 120.4M | 134.2M | 89.0M | 21.6M |
| Selling, general and administrative | 511.3M | 28.9M | 21.0M | 22.0M | 21.3M | 18.5M | 90.5M | 34.4M | 4.87M |
| Operating income | 4.68M | -119.7M | -202.0M | -226.3M | -297.5M | -186.2M | -194.8M | -148.1M | -44.4M |
| Depreciation and amortization | 59.8M | 61.3M | 60.7M | 51.5M | 43.9M | 24.4M | 22.2M | 11.7M | 10.1M |
| EBITDA | 64.5M | -58.3M | -141.3M | -174.7M | -253.6M | -161.8M | -172.6M | -136.4M | -34.3M |
| Interest expense | 10.5M | 10.6M | 9.58M | 7.19M | 2.40M | 3.94M | 7.70M | 4.48M | 3.33M |
| Income before tax | 4.05M | -127.9M | -209.4M | -210.8M | -291.7M | -184.6M | -202.5M | -152.6M | -47.7M |
| Income tax | -51.6M | -199.0K | 2.48M | -2.83M | |||||
| Net income | 55.7M | -127.9M | -209.4M | -210.6M | -291.7M | -188.6M | -210.2M | -124.9M | -31.1M |
| Earnings per share, basic | 0.01 | -0.03 | -0.05 | -0.05 | -0.07 | -0.05 | -0.05 | -0.03 | -0.01 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 109.3M | 89.3M | 173.3M | 33.6M | 81.6M | 484.8M | 588.7M | 198.2M | 76.4M |
| Short-term investments | 0 | 15.0M | 0 | 179.2M | |||||
| Receivables | 163.9M | 96.1M | 19.4M | 9.53M | 793.0K | 1.22M | 6.88M | 2.27M | 484.0K |
| Inventory | 136.6M | 111.0M | 102.0M | 100.8M | 53.2M | 33.4M | 22.2M | 27.6M | 36.3M |
| Current assets | 434.5M | 365.8M | 342.2M | 201.1M | 247.8M | 569.1M | 955.1M | 260.8M | 154.9M |
| Property, plant and equipment | 569.0M | 614.2M | 686.5M | 704.0M | 561.0M | 512.6M | 332.4M | 122.8M | 113.1M |
| Total assets | 1.15B | 1.02B | 1.03B | 917.5M | 899.9M | 1.16B | 1.40B | 473.2M | 289.1M |
| Accounts payable | 30.2M | 11.7M | 10.0M | 16.6M | 12.9M | 4.52M | 4.51M | 1.80M | 1.09M |
| Current liabilities | 534.3M | 312.1M | 316.2M | 188.4M | 235.0M | 202.6M | 270.3M | 156.4M | 70.9M |
| Long-term debt | 66.3M | 165.5M | 101.5M | 84.7M | 0 | 0 | 65.0M | 65.0M | |
| Total debt | 326.9M | 293.1M | 260.1M | 126.3M | 46.4M | 40.3M | 214.3M | 105.0M | 75.0M |
| Total liabilities | 996.6M | 927.3M | 829.9M | 516.6M | 297.9M | 281.6M | 342.8M | 223.7M | 135.9M |
| Shareholders' equity | 157.4M | 88.9M | 205.1M | 400.9M | 602.0M | 881.5M | 1.05B | 249.6M | 99.8M |
| Shares outstanding | 4.12B | 4.12B | 4.12B | 4.12B | 4.12B | 4.12B | 4.12B | 4.12B | 4.12B |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 80.8M | -4.10M | 57.4M | -56.9M | -199.5M | -147.2M | -136.6M | -61.9M | -65.1M |
| Capital spending | -104.0M | -59.5M | -19.0M | -125.1M | -148.7M | -197.2M | -113.6M | -90.9M | -13.1M |
| Free cash flow | -23.2M | -63.6M | 38.4M | -182.0M | -348.1M | -344.5M | -250.2M | -152.8M | -78.3M |
| Cash from investing | -64.2M | -98.2M | -3.50M | -105.0M | -179.4M | 156.0M | -413.1M | -82.7M | -13.6M |
| Cash from financing | 3.29M | 18.3M | 85.6M | 112.3M | -17.8M | -80.5M | 922.8M | 256.8M | 16.9M |
| Share buybacks | 0 | 1.03B | 410.5M | 0 | |||||
| Change in cash | 19.9M | -84.0M | 139.8M | -48.0M | -403.3M | -103.9M | 390.5M | 121.8M | -33.2M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026 | Nov 3, 2026 | Monthly return | HKEX |
| Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026 | Oct 6, 2026 | Monthly return | HKEX |
| 2026 Interim Report | Sep 21, 2026 | Interim report | HKEX |
| THIRD AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION | Jun 26, 2026 | Other filings | HKEX |
| VOLUNTARY ANNOUNCEMENT APPROVAL FROM THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ON THE NEW DRUG APPLICATION (NDA) OF OUR PIPELINE PRODUCT, CMAB807X (DENOSUMAB INJECTION) | Jun 24, 2026 | Operations update | HKEX |
Cap table
Built by 6ix from Mabpharm Limited’s releases
- Common shares
- 4,124,080,000
- Fully diluted
- 4,124,080,000
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 4,124,080,000 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 4,124,080,000 |
Log in to ask 6ix AI your own questions about Mabpharm Limited.